Meloxicam Rompharm (Meloxicam)

Meloxicam works by inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for the synthesis of prostaglandins. By reducing prostaglandin production, the drug decreases inflammation, pain, and fever at the site of tissue injury, providing therapeutic benefit in musculoskeletal disorders.

The dosage of Meloxicam Rompharm is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. The prescriber will select the appropriate strength, frequency, and duration in accordance with clinical guidelines and individual patient needs.

Meloxicam should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider before starting therapy.

To order Meloxicam Rompharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Meloxicam offers a relatively longer half‑life and greater COX‑2 selectivity compared with many traditional NSAIDs, which may allow once‑daily dosing and potentially lower gastrointestinal toxicity. However, it shares similar cardiovascular and renal risk profiles, so clinicians weigh these factors against patient‑specific considerations when selecting therapy.

Meloxicam Rompharm should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, consult the supplier for guidance before use.

Meloxicam Rompharm is supplied as an injectable solution for intramuscular injection. The healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and according to the prescribed dosing schedule.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as myocardial infarction or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), hepatic injury, and renal impairment. Patients should be monitored for signs of these conditions, and therapy should be discontinued if they occur.

Meloxicam Rompharm is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding, severe heart failure, or severe renal or hepatic impairment. It should also be avoided in patients who have had a recent coronary artery bypass graft surgery.